Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Company Announcement - Cogent Biosciences, Inc. will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 7:35 a.m. ET [1] - A live webcast of the presentation will be available on the Investors & Media page of Cogent's website, with a replay accessible approximately two hours after the event and archived for 30 days [2] Inducement Grants - On May 19, 2025, Cogent's Compensation Committee approved "inducement" equity awards for five new employees under the 2020 Inducement Plan, with a grant date of May 27, 2025 [3] - The total awards consist of nonqualified options to purchase 127,000 shares of Cogent common stock, with a 10-year term and an exercise price equal to the closing price on the grant date [3] - The options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in equal monthly installments over the following 36 months, contingent on continued employment [3] Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [4] - The KIT D816V mutation is linked to systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST), which rely on oncogenic KIT signaling [4] - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing targeted therapies for mutations in ErbB2, PI3Kα, and KRAS [4]